title: DX-890 (Dyax).
abstract: Dyax (formerly Protein Engineering Corp) and Debiopharm are developing DX-890, an inhibitor of human neutrophil elastase (HNE), for the potential treatment of pulmonary diseases such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) [242806]. In December 1999, Debiopharm initiated phase I trials with an aerosol formulation of DX-890; studies were completed by October 2000 [350718], [352554], [387155]. By August 2000, DX-890 was in phase II evaluation for the potential treatment of CF [378625], and in May 2002, Dyax planned to initiate a further study, in children with CF, within the year [451044]. By June 2002, phase II trials in CF were ongoing in France and Spain, with results expected soon after this date [454485]. In September 2000, JP Morgan predicted a 2005 launch for this drug, with estimated sales in that year of 23 US dollars million rising to 63 million US dollars in 2007 [397766].
authors.affiliation: Southampton General Hospital, RCMB Research Division, Tremona Road, Southampton, SO16 6YD, UK. p.wark@soton.ac.uk
authors.forename: Peter A B
authors.initials: PA
authors.lastname: Wark